- Investing Ideas
- Global Pharmaceuticals & Biotech Top Growth Stocks
Global Pharmaceuticals & Biotech Top Growth Stocks
Results
67
67 companies
Sichuan Kelun-Biotech Biopharmaceutical
Market Cap: HK$97.5b
A biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, metabolism, and other therapeutic areas in the People’s Republic of China and internationally.
6990
HK$418.00
7D
0.5%
1Y
27.8%
Madrigal Pharmaceuticals
Market Cap: US$11.8b
A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
MDGL
US$512.65
7D
1.4%
1Y
70.5%
Axsome Therapeutics
Market Cap: US$12.4b
A biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States.
AXSM
US$241.67
7D
-3.5%
1Y
133.8%
Syndax Pharmaceuticals
Market Cap: US$1.9b
A commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer.
SNDX
US$21.31
7D
12.2%
1Y
135.7%
Camurus
Market Cap: SEK 32.8b
A biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia.
CAMX
SEK 551.00
7D
6.2%
1Y
-9.3%
Oscotec
Market Cap: ₩1.3t
Operates as a biotechnology company, engages in the drug development, functional materials and related products, and dental bone graft material businesses.
A039200
₩35,150.00
7D
-5.4%
1Y
18.2%
Starpharma Holdings
Market Cap: AU$292.7m
A biopharmaceutical company, engages in the research, development and commercialization of dendrimer technology for pharmaceutical, healthcare applications, life science, and other applications in Australia and internationally.
SPL
AU$0.69
7D
0%
1Y
672.2%
Bonesupport Holding
Market Cap: SEK 13.5b
An orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in the United States, Europe, and internationally.
BONEX
SEK 205.40
7D
-2.5%
1Y
-27.5%
Kuros Biosciences
Market Cap: CHF 721.0m
Engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally.
KURN
CHF 18.28
7D
-1.2%
1Y
-35.1%
HansBiomed
Market Cap: ₩350.1b
Engages in the research and development, production, and sale of medical materials for the procedure and the raw materials for medical supplies.
A042520
₩24,550.00
7D
0.2%
1Y
178.3%
Ardelyx
Market Cap: US$1.4b
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
ARDX
US$5.55
7D
-8.3%
1Y
50.4%
Cutia Therapeutics
Market Cap: HK$981.1m
An investment holding company, engages in the research, development, manufacture, and commercialization of scalp diseases and care products, and skin care products in the People’s Republic of China and Hong Kong.
2487
HK$2.70
7D
-15.6%
1Y
-71.3%
Pharma Mar
Market Cap: €1.3b
A biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Germany, Ireland, France, Switzerland, rest of the European Union, the United States, and internationally.
PHM
€73.00
7D
5.0%
1Y
-8.8%
Ocumension Therapeutics
Market Cap: HK$3.5b
Engages in the research, discovery, development, and commercialization of ophthalmic therapies in China.
1477
HK$4.35
7D
-11.0%
1Y
-58.3%
Lineage Cell Therapeutics
Market Cap: US$319.1m
A clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally.
LCTX
US$1.28
7D
5.8%
1Y
36.9%
Forum Markets
Market Cap: US$81.1m
A financial technology company, develops a blockchain-based platform focused on the acquisition, structuring, and tokenization of real-world assets worldwide.
FRMM
US$5.58
7D
10.5%
1Y
-32.8%
Alnylam Pharmaceuticals
Market Cap: US$38.9b
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.
ALNY
US$291.37
7D
4.8%
1Y
-9.7%
Zevra Therapeutics
Market Cap: US$799.2m
A commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States.
ZVRA
US$13.52
7D
4.8%
1Y
50.2%
Capricor Therapeutics
Market Cap: US$1.5b
A clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.
CAPR
US$26.44
7D
-6.8%
1Y
137.1%
DBV Technologies
Market Cap: €850.5m
A clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France.
DBV
€2.87
7D
1.5%
1Y
86.4%
Aldeyra Therapeutics
Market Cap: US$110.4m
A biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases.
ALDX
US$1.83
7D
-6.6%
1Y
-51.7%
ARS Pharmaceuticals
Market Cap: US$848.0m
A biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally.
SPRY
US$8.54
7D
-11.5%
1Y
-53.1%
Bora Pharmaceuticals
Market Cap: NT$52.5b
Engages in contract development, manufacture, and sale of pharmaceuticals in Europe, the United States, Taiwan, and internationally.
6472
NT$412.00
7D
-2.5%
1Y
-39.5%
Oxford Biomedica
Market Cap: UK£765.4m
A contract development and manufacturing organization, focuses on delivering therapies to patients worldwide.
OXB
UK£6.33
7D
5.5%
1Y
100.3%
AC Immune
Market Cap: US$254.0m
A clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding.
ACIU
US$2.56
7D
6.7%
1Y
27.4%
CG Oncology
Market Cap: US$6.3b
A late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States.
CGON
US$71.96
7D
17.8%
1Y
177.3%
MindMaze Therapeutics Holding
Market Cap: CHF 33.0m
Operates as a commercial-stage biopharmaceutical and neurotechnology company in Asia, the United States, Switzerland, rest of Europe, and internationally.
MMTX
CHF 0.22
7D
0.5%
1Y
n/a
Arcutis Biotherapeutics
Market Cap: US$3.4b
A biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
ARQT
US$27.00
7D
3.0%
1Y
96.5%
Genovis AB (publ.)
Market Cap: SEK 1.3b
Develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia.
GENO
SEK 19.46
7D
6.2%
1Y
-27.7%
Devyser Diagnostics
Market Cap: SEK 1.4b
Provides diagnostic kits and advanced analysis services for clinical genetics and post-transplantation laboratories in Sweden, rest of Europe, the Middle East, and Africa.
DVYSR
SEK 85.00
7D
-2.0%
1Y
-29.8%
Insmed
Market Cap: US$22.4b
Develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
INSM
US$103.38
7D
7.9%
1Y
3.9%
NewAmsterdam Pharma
Market Cap: US$3.9b
A late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease.
NAMS
US$33.24
7D
11.4%
1Y
79.0%
Belite Bio
Market Cap: US$5.9b
A clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States.
BLTE
US$148.73
7D
1.8%
1Y
151.9%
SIGA Technologies
Market Cap: US$281.2m
A commercial-stage pharmaceutical company, focuses on the health security market in the United States.
SIGA
US$3.92
7D
-9.3%
1Y
-39.3%
Healios K.K
Market Cap: JP¥33.2b
Engages in the research, development, manufacturing, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States.
4593
JP¥246.00
7D
-4.7%
1Y
-45.6%
Rhythm Pharmaceuticals
Market Cap: US$7.5b
A commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally.
RYTM
US$109.84
7D
13.5%
1Y
75.1%